| Autor: |
Ssali, F., Stöhr, W., Munderi, P., Reid, A., Walker, A. S., Gibb, D. M., Mugyenyi, P., Kityo, C., Grosskurth, H., Hakim, J., Byakwaga, H., Katabira, E., Derbyshire, J. H., Charles Gilks |
| Jazyk: |
angličtina |
| Rok vydání: |
2016 |
| Předmět: |
|
| Zdroj: |
Scopus-Elsevier |
| Popis: |
Objective To describe the prevalence, incidence and predictors of severe anaemia in previously untreated symptomatic HIV-infected adults with CD4+ T-cells 3 initiating zidovudine-containing regimens in Africa. Design DART is a randomized trial comparing two strategies for HIV/AIDS management in Uganda and Zimbabwe. Methods We analysed the occurrence of anaemia at weeks 4 and 12, and then every 12 weeks. We also evaluated sex, age, WHO stage, body mass index (BMI), baseline laboratory measurements and first regimen as predictors of developing grade 4 anaemia (Results To May 2005, 3,314 participants (65% women, 23% at WHO stage 4, median age=37 years, baseline CD4+ T-cell=86 cells/mm3 and median baseline haemo-globin=11.4 g/dl) had a median 72 weeks follow-up. Prevalence of grade 4 anaemia was 0.7%, 2.0%, 0.5% and + T-cell count and BMI at baseline were at significantly higher risk ( PConclusions We observed a higher incidence of grade 4 anaemia than in studies from industrialized countries, which is likely to be due in part to population characteristics and in part to a higher rate of concurrent HIV-related clinical events. Clinical vigilance and haemoglobin measurements 4, 8 and 12 weeks after starting zidovudine could help to manage serious anaemia. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
